SC
BBOT

Stempoint Capital’s BridgeBio Oncology BBOT Stock Holding History

Stempoint Capital’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-86,517
Closed -$1.08M – 119
2025
Q4 		$1.08M Sell
86,517
-100,097
-54% -$1.21M 0.19% 66
2025
Q3 		$2.16M Sell
186,614
-129,198
-41% -$1.35M 0.43% 48
2025
Q2 		$3.29M Buy
315,812
+114,912
+57% +$1.24M 1.06% 29
2025
Q1 		$2.27M Hold
200,900
– – 0.72% 34
2024
Q4 		$2.11M Buy
200,900
+900
+0.5% +$9.47K 0.53% 41
2024
Q3 		$2.09M Hold
200,000
– – 0.63% 38
2024
Q2 		$2.04M Hold
200,000
– – 0.6% 39
2024
Q1 		$2.08M Buy
+200,000
New +$2.07M 0.55% 36

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stempoint Capital's BBOT Position: Q1 2026 in Review

Stempoint Capital sold out of BridgeBio Oncology (BBOT) in Q1 2026, closing a stake of 86,517 shares — an estimated $1.08M sold.

Stempoint Capital first reported a position in BBOT in Q1 2024 and held it in 8 quarters. The position peaked at $3.29M in Q2 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Stempoint Capital reported no remaining BridgeBio Oncology position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 86,517 BridgeBio Oncology shares in Q1 2026, an estimated $1.08M.
  • Stempoint Capital first reported a position in BridgeBio Oncology in Q1 2024 and held it in 8 quarters.
  • Stempoint Capital's BridgeBio Oncology position peaked at $3.29M in Q2 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.